Regeneron Pharmaceuticals Stock Plummets 8.34% in Two Days, Trading Volume Ranks 190th with $9.08 Billion Turnover

On April 4, 2025, Regeneron Pharmaceuticals (REGN) experienced a significant decline in its stock price, dropping by 6.09% over two consecutive days, resulting in a total decrease of 8.34%. The trading volume for the day was substantial, with a turnover of $9.08 billion, placing it at the 190th position in the daily stock market rankings.

Oppenheimer has adjusted its price target for Regeneron Pharmaceuticals, lowering it from $950 to $925. This adjustment comes as part of a broader analyst consensus that maintains an overall positive outlook on the company's stock. The average price target for Regeneron, as polled by FactSet, stands at $935.91, reflecting a generally optimistic view among analysts.

Regeneron's stock has been under scrutiny due to various factors, including market volatility and regulatory concerns. Analysts have noted that the company's strong pipeline and innovative products continue to drive investor interest, despite recent setbacks. The stock's performance has been closely watched, with some analysts suggesting that the current price may present a buying opportunity for long-term investors.